Moreover, we found that histone citrullination was a promising therapeutic target to block disease progression, as the specific PADI4 inhibitor GSK48410 prevented further AAA growth when applied to established aneurysmatic lesions.20 Here, PADI4 is linked to triple-A syndrome.